Background In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare effi cacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in coinfected patients.
Introduction
Tuberculosis is the main opportunistic infection and a leading cause of death in people living with HIV. Antiretroviral therapy reduces mortality in patients coinfected with HIV and tuberculosis and should be started during the fi rst 8 weeks of tuberculosis treatment, irrespective of the patient's CD4 cell count. 1 Nevirapine and efavirenz are non-nucleoside reverse transcriptase inhibitors (NNRTIs) recommended by WHO as fi rst-line antiretroviral therapy. 1 Nevirapine is the most commonly used drug in resource-poor countries with a high HIV burden because of the convenience and aff ordability of generic fi xed-dose combinations.
Rifampicin is a key component of tuberculosis treatment but also a potent inducer of some forms of hepatic cytochrome P450, leading to enhanced NNRTI drug clearance and, consequently, reduced drug exposure. Nevirapine biotransformation pathways are more sensitive to induction than are those of efavirenz, and nevirapine-based regimens therefore have a greater risk of subtherapeutic NNRTI concentrations. [2] [3] [4] [5] The reduction in nevirapine concentration is most pronounced during the fi rst 2 weeks of antiretroviral therapy, when it is typically prescribed at half dose (200 mg lead-in dose) to prevent hypersensitivity before a steady state concentration has been reached. 6 To avoid this problem, WHO guidelines recommend efavirenz rather than nevirapine for patients co-infected with HIV and tuberculosis. 1 However, efavirenz has other diffi culties, primarily its toxic eff ects on the CNS that can necessitate discontinuation of early treatment. 7 Moreover, because of efavirenz's potential teratogenicity, use during the fi rst trimester of pregnancy is controversial. 1, 8, 9 For national HIV programmes, fi xed-dose combinations containing efavirenz (efavirenz-lamivudine-tenofovir and efavirenztenofovir-emtricitabine) are less aff ordable than are fi xeddose combinations based on nevirapine. 10 Assessment of the eff ects of giving rifampicin with nevirapine on virological outcome has yielded confl icting results in clinical studies of nevirapine given with a 2 week lead-in dose. [11] [12] [13] [14] These discrepancies led some authors to propose that, because cytochrome P450 enzymes in patients on rifampicin are presumably already induced at the time of antiretroviral therapy initiation, nevirapine should be started at full dose in these patients. 15, 16 However, effi cacy and safety of this approach have not been assessed. In this study, we aimed to compare the effi cacy and safety of nevirapine-based and efavirenz-based antiretroviral therapies in patients co-infected with HIV and tuberculosis, with initiation of nevirapine at full dose.
Methods

Study design and participants
The comparison of nevirapine and efavirenz for the treatment of HIV-tuberculosis co-infected patients (French Research Agency for HIV/AIDS and hepatitis [ANRS] 12146 CARINEMO) trial was an open-label, randomised, phase 3 non-inferiority trial done at three health centres in Maputo, Mozambique: José Macamo Hospital, Mavalane Hospital, and Alto Maé Health Centre. We enrolled adults (≥18 years) with previously untreated HIV infection who had been receiving treatment for pulmonary or extrapulmonary tuberculosis for less than 4 weeks at tuberculosis or HIV outpatient clinics in three health areas of Maputo. We enrolled participants if they had a Karnofsky score of 60% or more (ambulatory patients), CD4 cell count of less than 250 cells per μL, a negative urine pregnancy test, alanine aminotransferase and total bilirubin concentrations of less than fi ve times the upper limit of normal (ULN; grade <3), and absence of any grade 4 clinical or biological adverse event. Women who had previously received one dose of nevirapine or zidovudine-nevirapine for prevention of mother-to-child trans mission of HIV were eligible for inclusion.
We followed good clinical practice guidelines and four ethics committees approved the study protocol: the Comité Nacional de Bio-Ética para a Saúde (Maputo, Mozambique), the Médecins Sans Frontières Ethics Review Board (Zurich, Switzerland), the Comité de Protection des Personnes (Saint Germain-en-Laye, France), and the Columbia University ethics review committee (New York, NY, USA). All participants provided signed informed consent.
Randomisation and masking
4-6 weeks after starting tuberculosis treatment, we randomly allocated patients (1:1) to receive either nevirapine or efavirenz regimens. Randomisation was done centrally at Epicentre headquarters (Paris, France) and treatment allocation was communicated to the site investigators sequentially for consecutive enrolment of patients. The allocation sequence was computergenerated with block sizes of two to six (in steps of two), stratifi ed by site and CD4 cell count (≤50 cells per μL vs >50 cells per μL). Randomisation lists were prepared by the trial statistician (EB) and concealed from the site investigators. Masking of investigators and patients to treatment allocation would have required use of placebo and was not feasible in this context. Before closure of the trial sites, aggregated data by treatment group were available only to the trial statistician and the independent data monitoring committee (IDMC).
Procedures
All patients received the standard national tuberculosis chemotherapy of a generic fi xed-dose combination of once-daily tablets combining rifampicin (150 mg), isoniazid (75 mg), pyrazinamide (400 mg), and ethambutol (275 mg) for the fi rst 2 months, followed by isoniazid (75 mg) and rifampicin (150 mg) for the subsequent 4 months (Lupin, Aurangabad, India), at a dose of 10 mg/kg (rifampicin), 5 mg/kg (isoniazid), 25 mg/kg (pyrazinamide), and 15 mg/kg (ethambutol). Antiretroviral therapy was started after patients received 2 weeks of counselling, which involved psychosocial Figure 1 : Study profi le *One patient was incarcerated during follow-up, one had an exacerbation of a chronic psychotic disorder that prevented retention in the trial, and one had baseline monoresistance to rifampicin and was referred to the national multidrug-resistant tuberculosis programme. The protocol allowed substitution of nevirapine by efavirenz in cases of severe hepatitis (alanine aminotransferase >5×ULN) or rash (grade ≥3), and substitution of efavirenz by nevirapine during the fi rst trimester of pregnancy for women who became pregnant during follow-up. Tenofovir replaced stavudine or zidovudine in patients who developed lactic acidosis, as measured by lactic acid concentration in symptomatic patients, and in patients co-infected with hepatitis B and presenting with severe hepatitis. According to 2006 WHO and national guidelines, patients with HIV-1 RNA counts of more than 10 000 copies per mL on two consecutive measures and reinforcement of treatment adherence were switched to an adapted boosted protease inhibitorbased antiretroviral therapy after approval by the national antiretroviral committee. All patients received pyridoxine (50 mg per day) during tuberculosis treatment and 960 mg co-trimoxazole per day.
We did clinical examination and laboratory analyses at screening and inclusion visits, at weekly visits for the fi rst 8 weeks after randomisation, and thereafter every 4 weeks. Patients were diagnosed with pulmonary tuberculosis and started tuberculosis treatment at clinics before referral to the trial site. Diagnosis of pulmonary tuberculosis was based on the results of two sputum smear-examination (on spot and early-morning specimens) or chest radiograph and response to an antibiotic trial for patients with smear-negative pulmonary tuberculosis. Extrapulmonary tuberculosis was diagnosed with cytohistopathology, biochemical, and radiographical assessment. For patients with pulmonary tuberculosis, two sputum samples were collected at the fi rst trial screening visit within 2 weeks after start of tuberculosis treatment and were shipped to the reference laboratory at the Institute of Tropical Medicine (Antwerp, Belgium) for culture and drug-susceptibility testing. Sputummicroscopy was also done at 2, 4, and 6 months after start of tuberculosis treatment. We took chest radio graphs and full blood counts at the screening visit for all patients.
We diagnosed hepatitis B (defi ned as detection of hepatitis B surface antigen and hepatitis B core antibody) and hepatitis C (defi ned as detection of hepatitis C virus antibody with two ELISA tests and confi rmation by the detection of hepatitis C virus-RNA at the Necker Hospital, Paris, France) at the inclusion visit. We measured plasma HIV-1 RNA with the Roche Cobas Amplicor HIV-1 monitor test v1.5 (Roche Diagnostics, Basel, Switzerland) at the inclusion visit and at weeks 12, 24, 36, and 48; CD4 cell count was assessed at screening visit, week 24, and week 48. Resistance mutations to nucleoside reverse transcriptase inhibitors and NNRTI were determined in all patients with HIV-1 RNA counts of more than 400 copies per mL at week 48 by sequencing the reverse transcriptase gene with the consensus technique of the Data are n (%), median (IQR), or n/N (%). ULN=upper limit of normal. HBV=hepatitis B virus. HCV=hepatitis C virus. *19 patients in the nevirapine group and 11 patients in the efavirenz group were not able to produce sputum specimen for microscopy test. We assessed intensity of adverse events with the ANRS table for grading adult adverse event (grade 1 was defi ned as mild, grade 2 as moderate, grade 3 as severe, and grade 4 as lifethreatening). 18 We defi ned serious adverse events as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospital admission or prolongation of hospital stay, resulted in disability or incapacity, or resulted in a congenital anomaly or birth defect. We obtained blood samples for measurement of nevirapine and efavirenz plasma concentration every 12 weeks. To verify the absence of major changes in metabolism of nevirapine caused by rifampicin, the IDMC requested a full pharmacokinetic analysis in the fi rst 20 patients enrolled in the nevirapine group 4 weeks after co-administration with rifampicin and also 4 weeks after completion of tuberculosis treat ment. 19 The protocol was amended in January, 2010 to extend follow-up until week 96 for the last enrolled patients with HIV-1 RNA and CD4 cell count measured at 72 weeks and 96 weeks (appendix). Results of the extended follow-up will be presented separately.
The primary outcome was virological suppression at week 48, defi ned as an HIV-1 RNA count of less than 50 copies per mL. Patients who died or were lost to follow-up before week 48 were categorised as treatment failures. Secondary outcomes were increase in CD4 cell count by more than 20% from baseline to week 48, occurrence of AIDS-defi ning events, end of tuberculosis treatment outcomes as per WHO defi nitions, occur rence of treatment-emergent adverse eff ects (TEAE), and paradoxical tuberculosis immune reconstitution infl ammatory syndrome (IRIS) within 12 weeks of start of antiretroviral therapy. 20, 21 Members of the trial's scientifi c advisory board (RB and CM) validated causes of death and IRIS-tuberculosis. Adverse event terms were adopted from the medical dictionary for regulatory activities (MedDRA version 11.1).
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Statistical analysis
We defi ned the non-inferiority margin for the diff erence in effi cacy as 10%. Assuming a 70% effi cacy in the efavirenz group 23 and a maximum diff erence of 10% in effi cacy between two groups, a sample size of 260 patients per group was needed to determine non-inferiority with a power of 80% and an α level of 5% (one-sided test; nQuery Advisor version 6). We increased the proposed sample size by 10% to account for loss to follow-up.
Data were reviewed by the IDMC every 6 months. We did effi cacy analyses for two populations: the intentionto-treat population, which included all randomised patients who received at least one dose of allocated drug; and the per-protocol population, excluding participants who discontinued treatment prematurely for reasons other than death or loss to follow-up, who had a treatment adherence of less than 80%, who had NNRTI substitution, or who did not have HIV-1 RNA results at week 48. We did a sensitivity analysis of effi cacy in the intention-totreat population, classifying treatment failures as patients who had NNRTI substitution, including substitution because of pregnancy (switch equals failure analysis). We tested non-inferiority of the nevirapine regimen with the Blackwelder method by calculating the diff erence in effi cacy between the efavirenz and nevirapine regimens and comparing the upper limit of the 90% CI (as specifi ed in the sample-size calculation based on a one sided-test and a 5% α error) to the non-inferiority margin. 24 Therefore, to accept non-inferiority of the nevirapine regimen, the upper limit of the 90% CI needed to be equal or less than 10%. Secondary analyses included estimation of the proportion of patients with HIV-1 RNA levels of less than 50 copies per mL at weeks 12, 24, 36, and 48. For patients who had NNRTI substitution, we used only HIV-1 RNA results before substitution. Other secondary analyses included antiretroviral therapy effi cacy at 48 weeks with an HIV-1 RNA detection limit of 400 copies per mL in the per-protocol population; the proportion of patients with an increase in CD4 cell count by 20% or more from baseline to week 48; the proportion of patients with an incident AIDS-defi ning disease; and end of tuberculosis treatment outcomes and the proportion of tuberculosis with paradoxical IRIS. For safety analysis, we report the proportion of patients who had at least one TEAE, major TEAE (grade ≥3), serious TEAE, or TEAE of interest (grade ≥3 hepatitis and rash) by treatment group. We report the proportion of patients with an increase of alanine aminotransferase (grade ≥2) during follow-up and by group. We compared proportions with χ² or Fisher's exact tests with two-sided p values. Data were analysed with Stata version 10.1. This study is registered with ClinicalTrials.gov, number NCT00495326.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. EB had full access to all the data in the study and MB had fi nal responsibility for the decision to submit for publication.
Results
We enrolled 573 patients between October, 2007, and March, 2010, and completed follow-up in February, 2011 (fi gure 1). Because of a temporary hold on inclusions placed by the IDMC in October, 2007, which was justifi ed by the investigators' decision to abandon the 2 week nevirapine lead-in dose on the basis of preliminary results from a large South African prospective cohort, 14 three patients were started on efavirenz regimen without randomisation. 43 (15%) of 285 patients randomly allocated nevirapine and 52 (18%) of 285 patients randomly allocated efavirenz did not complete 48 weeks of followup (p=0·3118).
In the nevirapine group, 17 patients discontinued follow-up before 12 weeks (13 deaths, three losses to follow-up, and one referral to treatment for multidrugresistant tuberculosis), 12 discontinued follow-up at 12-24 weeks (seven voluntary withdrawals, four referrals to treatment for multidrug-resistant tuber culosis, one death, and one referral to psychiatric treatment), and 14 discontinued follow-up after 24 weeks (eight voluntary withdrawals, four deaths, one loss to follow-up, and one incarceration). In the efavirenz group, 15 patients discontinued follow-up before 12 weeks (eight deaths, three losses to follow-up, three voluntary withdrawals, and one referral to treatment for multidrug-resistant tuberculosis); 20 discontinued follow-up at 12-24 weeks (11 voluntary withdrawals, fi ve deaths, and four losses to follow-up) and 17 discontinued follow-up after 24 weeks (13 voluntary withdrawals, three deaths, and one loss to follow-up). Of 42 voluntary withdrawals, 18 moved to South Africa and 13 moved to another region in Mozambique for work reasons, ten refused to continue follow-up in the trial, and one was unable to participate because of drug addiction. Fewer patients withdrew voluntarily in the nevirapine group (15 patients [5%]) than in the efavirenz group (27 patients [9%]; p=0·0544). 15 patients substituted from nevirapine to efavirenz (14 because of toxic eff ects and one because of protocol deviation) and six patients substituted from efavirenz to nevirapine (four because of pregnancy and two because of neurological toxic eff ects). Table 1 shows baseline characteristics of patients. Although not signifi cantly diff erent, slightly fewer patients had smear-positive pulmonary tuberculosis in the nevirapine group than the efavirenz group (p=0·0584). The median time between start of tuberculosis treatment and sputum collection for Mycobacterium tuberculosis culture was 14 days (IQR 8-20) for nevirapine and 12 days (7-18) for efavirenz. After exclusion of failure of specimen shipment (12 samples in the nevirapine group vs Two patients were allocated the incorrect drug because of an incorrect stratifi cation by CD4 cell count but were retained in the intention-to-treat population. After exclusion of patients who discontinued prematurely for reasons other than death or loss to follow-up (voluntary withdrawals, withdrawals due to multidrug resistance, or other reasons; fi gure 1), patients with NNRTI substitution, patients with antiretroviral therapy adherence lower than 80% (four patients in the nevirapine group vs two patients in the efavirenz group), and patients who completed follow-up but did not have an HIV-1 RNA measurement at week 48 (two vs three), we included 243 patients from the nevirapine group and 246 patients from the efavirenz group in the per-protocol analysis.
Antiretroviral therapy effi cacy (HIV-1 RNA <50 copies per mL) at 48 weeks was 64·6% for nevirapine and 69·8% for efavirenz in the intention-to-treat population and 70·0% vs 78·9% in the per-protocol population (fi gure 2 and table 2). Non-inferiority of the nevirapine regimen was not shown. The one-sided 95% CI of the efavirenznevirapine effi cacy diff erence exceeded the predefi ned 10% non-inferiority margin in intention-to-treat, perprotocol, and switch-equals-failure analysis (fi gure 2 and table 2). 15 patients who substituted nevirapine with efavirenz had virological suppression at week 48. Two of four patients who substituted efavirenz with nevirapine because of pregnancy had no virological suppression at week 48 and one had confi rmed NNRTI resistance.
Although the proportion of patients with an HIV-1 RNA count of less than 50 copies per mL was lower in the nevirapine group than in the efavirenz group, the diff erence was not signifi cant beyond 12 weeks (fi gure 3). Incidence of AIDS-defi ning illness, increase in CD4 cell count, and the proportion of patients at week 48 with an HIV-1 RNA count of less than 400 copies per mL did not diff er between groups (table 2) . Antiretroviral resistance genotyping results (table 3) were available for 49 (79%) of 62 patients who had HIV-1 RNA levels of more than 400 copies per mL at week 48. All reverse transcriptase gene sequences corresponded to HIV-1 subtype C.
Tuberculosis treatment success (cured or completed) was more than 90% in both groups (table 4). 32 patients in the nevirapine group (11%) and 21 in the efavirenz group (7%) had paradoxical associated tuberculosis IRIS (p=0·1039).
The number of TEAEs was much the same in both groups (table 5) . 18 patients in the nevirapine group died, as did 17 patients in the efavirenz group (one patient allocated efavirenz died without been randomly allocated). Cause of death was determined for 29 (83%) of 35 deaths and included tuberculosis (three deaths in the nevirapine group vs fi ve in the efavirenz group), severe infection (three vs three), IRIS-tuberculosis (four vs none), IRISKaposi (one vs one), Kaposi sarcoma (two vs two), wasting syndrome (none vs two), tumour of hypopharynx (none vs one), Guillain-Barré syndrome (none vs one), and car accident (one vs none). No deaths were attributed to the study drugs. The proportion of patients with an increase of alanine aminotransferase during follow-up was much the same in both groups (fi gure 4). One patient in the nevirapine group had Stevens-Johnson syndrome that resolved after discontinuation of nevirapine. More patients in the nevirapine group (14 patients) than in the efavirenz group (two) dis continued because of toxic eff ects (p=0·002; table 5). 11 patients received tenofovir during follow-up (four for severe hepatitis with hepatitis B coinfection and seven for lactic acidosis or severe neuropathy with anaemia).
Discussion
To our knowledge, our study is the largest randomised non-inferiority trial to compare the effi cacy of nevirapinebased and efavirenz-based regimens in patients coinfected with HIV and tuberculosis, and the fi rst to use Treatment outcomes did not diff er between the two study groups. *Five patients were transferred to the national multidrug-resistant tuberculosis programme for treatment and one patient was incarcerated during follow-up. nevirapine without a lead-in dose. Non-inferiority of the nevirapine-regimen was not shown in our intention-totreat or per-protocol populations. However, rates of immune reconstitution, death, and incident AIDS events did not diff er between the two groups. Our switch-equalsfailure analysis in the intention-to-treat population favoured the efavirenz regimen, which resulted in six treatment substitutions compared with 15 for patients randomly allocated to receive the nevirapine regimen. All substitutions were made because of safety reasons or pregnancy and none was attributed to loss of effi cacy. Several reasons might explain why nevirapine did not show non-inferiority. One possibility is that the two tested regimens have the same effi cacy, and that the rifampicin interaction drives the diff erence in virological response. Indeed, the large non-inferiority randomised clinical 2NN trial 23 comparing nevirapine-based and efavirenzbased regimens in patients with HIV but not tuberculosis reported no signifi cant diff erences in virological effi cacy between groups at 48 weeks (HIV-1 RNA threshold of 50 copies per mL). A Cochrane meta-analysis 25 of seven randomised clinical trials (60% of participants were from the 2NN study 23 ) also failed to show a signifi cant diff erence between the two regimens. The 2NN study 23 thus could not show the non-inferiority of the nevirapinebased regimen. However, several fi ndings from our study suggest that the signifi cant diff erence in virological response between the two groups could have been attributable to nevirapine's lower intrinsic potency rather than to the interaction with rifampicin. First, the diff erence remained the same during and after tuberculosis treatment (which was discontinued at week 24) and seemed more pronounced at week 48. Second, although not representative of all patients, the nevirapine trough concentrations from the fi rst 20 patients enrolled in the trial showed a median minimum concentration of 4·9 mg/L, which is higher than the minimum therapeutic concentration of 3 mg/L. 19 Finally, the 48 week effi cacy of the nevirapine regimen in our study (64·6%) was in the range (61-69%) reported from randomised trials that used the same regimen in patients with HIV without tuberculosis co-infection. 23, [26] [27] [28] The hypothesis that nevirapine has a lower intrinsic antiviral potency than does efavirenz is also supported by recent results of the HIV-CAUSAL prospective cohort 29 which reported 54% more virological failures in patients after 12 months on an nevirapine regimen than on an efavirenz regimen, and by a review 30 of studies comparing nevirapine and efavirenz in tenofovir-based regimens, which concluded that nevirapine regimens also show increased rates of virological failure.
Our results diff er from those obtained in the two previous randomised trials comparing nevirapine-based and efavirenz-based regimens in patients co-infected with HIV and tuberculosis (panel). The N 2 R study 13 from Thailand did not report diff erences in 48 week effi cacy between the nevirapine (71·8%) and efavirenz (73·2%) regimens in their intention-to-treat population. However, the trial was not suffi ciently powered (140 patients) to show non-inferiority of the nevirapine regimen. The second study, a non-inferiority trial from India, 11 was halted by the IDMC because of a lower effi cacy noted in the nevirapine group (65%; once-daily nevirapine) than in the efavirenz group (85%) at week 24 with an HIV-1 RNA threshold of 400 copies per mL. A post-hoc analysis with the same cutoff in our trial did not show a signifi cant diff erence: 219 (77%) of 285 pa tients in the nevirapine group versus 230 (81%) of 285 in the efavirenz group (p=0·2599). These confl icting results might be explained by diff erences in nevirapine admin istration (once-daily vs twice-daily or whether escalating dosage was used), methodological diff erences, diff er ences in treatment adherence, and genetic diff erences in NNRTI disposition that lead to variability between individuals in plasma clearance, eff ect, and tolerance. 31 Although introduced at full dose, nevirapine was well tolerated in our study, with a low rate of severe biological hepatic toxicity (7%) compared with the 10% average reported in previous trials of patients with HIV without tuberculosis co-infection, and the proportion of severe rash was very low (1%). 32 This low incidence of rash was probably attributable to the low baseline CD4 cell counts in patients starting treatment in this trial but might be also explained by a genetic variation of nevirapine metabolism, resulting in diminished plasma concentration of the metabolite 12 hydroxy-nevirapine, which is associated with a lower risk of nevirapine-induced rash. 33 Our trial has several limitations. First, despite appropriate randomisation (baseline characteristics did not diff er between the two groups), slightly fewer patients with smear-positive pulmonary tuberculosis were enrolled in the nevirapine group than in the efavirenz group. Second, the proportion of patients who had pulmonary tuberculosis confi rmed with M tuberculosis culture was low in comparison with microscopy results. In Mozambique, such culturing is not part of routine tuberculosis diagnosis. However, in this trial it was done once patients were referred to the trial sites, on average, 2 weeks after the start of tuberculosis treatment, whereas microscopy tests were done before tuberculosis treatment was started at the clinic. Because of this delay, some cultures might have tested negative. Moreover, the challenges of shipping sputum samples abroad for this test resulted in a high rate of specimen contamination (7%). Third, several patients withdrew from the trial after migrating to South Africa during follow-up and were no longer able to access the study sites. Most of these patients left the trial after 24 weeks of follow-up and slightly more voluntary withdrawals occurred in the efavirenz arm, which could not be explained. Nonetheless, such a pattern of withdrawal is unlikely to be related to a poor efavirenz tolerability because most withdrawals occurred after 24 weeks after the start of antiretroviral therapy. Fourth, the risk of bias in investigators' management of an open-label design should not be ignored. However, the effi cacy outcome and hepatitis, one of the main safety outcomes, were established principally from laboratory results. Finally, the choice of a predefi ned 10% non-inferiority margin merits discussion. Some investigators, suggest adoption of a larger non-inferiority effi cacy margin of 12% with 95% power on the basis of HIV trials in previously untreated patients that suggest such trials are often overpowered because of an underestimation of the success rates and that a loss of effi cacy could be accepted . We identifi ed only two randomised controlled trials that compared nevirapine-based and efavirenz-based antiretroviral therapies in patients co-infected with HIV and tuberculosis treated with rifampicin. 11, 13 One of these trials 11 assessed once-daily nevirapine and was prematurely halted because of the reduced effi cacy (65%) in the nevirapine group compared with the efavirenz group (85%) at week 24. The other trial 13 did not show a signifi cant diff erence in the 48 week virological effi cacy between the nevirapine and efavirenz groups but was not powered to show non-inferiority of the nevirapine regimen. In both trials, the nevirapine-escalating dose was used, which could result in subtherapeutic nevirapine concentrations at antiretroviral therapy initiation in patients on rifampicin.
Interpretation
To our knowledge, our trial is the fi rst to compare a nevirapine regimen with an efavirenz regimen in patients co-infected with HIV and tuberculosis without use of a nevirapine escalating dose and the fi rst to have suffi cient power for a non-inferiority analysis. Although non-inferiority of the nevirapine regimen was not shown in our study, effi cacy results at 48 weeks were comparable with those reported for patients with HIV but not tuberculosis and the co-administration of nevirapine and rifampicin was well tolerated. Nevirapine might therefore be regarded as an acceptable alternative in patients unable to tolerate efavirenz or who have a contraindication to efavirenz.
if the new treatment has some other advantage. 34 In our trial, the estimated success rate was not underestimated but the choice of higher non-inferiority margin (12%) might have slightly changed the results of the trial but not the conclusion.
Few alternatives to efavirenz exist for patients coinfected with HIV and tuberculosis. Use of a triple nucleoside reverse transcriptase inhibitor regimen is not ideal because of its reduced effi cacy (especially in patients with a high HIV-RNA at treatment initiation) compared with the efavirenz regimen in patients with HIV without tuberculosis. 1, 23, 35 Replacement of rifampicin by rifabutin, a weaker enzyme inducer, would preclude use of a fi xeddose combination-based tuberculosis therapy (a cornerstone of the WHO tuberculosis control strategy), thereby making treatment much more expensive. 36 The use of a 600 mg maintenance dose of nevirapine has been also suggested but was associated with an increased rate of hypersensitivity reactions and premature termination of a randomised trial from Thailand. 37 Overall, non-inferiority of the nevirapine regimen in terms of effi cacy for patients co-infected with HIV and tuberculosis was not shown in this trial. This outcome might be attributed to a slightly reduced intrinsic potency of nevirapine compared with efavirenz rather than to coadministration with rifampicin. However, we also noted that initiation of nevirapine at full dose showed 48 week effi cacy results comparable with those reported for patients with HIV but not tuberculosis, and was well tolerated. Nevirapine could therefore be regarded as an acceptable alternative in patients unable to tolerate efavirenz or who have a contraindication to efavirenz.
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